Targeted Therapy on the Screen: Do We Hit the Target?

Clin Cancer Res. 2022 Dec 15;28(24):5233-5234. doi: 10.1158/1078-0432.CCR-22-2707.

Abstract

A phase II trial, investigating whether the antidiabetic drug metformin could reduce hypoxia in cervical cancer, used imaging to preselect patients and test the biological hypothesis behind the drug effect. This trial design would be of importance for the implementation of targeted treatment in the clinic. See related article by Han et al., p. 5263.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Female
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Metformin* / therapeutic use
  • Uterine Cervical Neoplasms* / diagnosis
  • Uterine Cervical Neoplasms* / drug therapy

Substances

  • Metformin
  • Hypoglycemic Agents